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Summary 24 
We investigated the interrelationships between serum metabolome, airway microbiome, and 25 
bronchiolitis severity, showing that the serum metabolome profiles differed by disease severity. 26 
Plasmalogen metabolites were associated with a lower severity and Streptococcus was negatively 27 
correlated with these plasmalogen pathway metabolites. 28 
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ABSTRACT 35 
Background Emerging evidence suggests relations of nasopharyngeal metabolome and microbiota 36 
with bronchiolitis severity. However, the influence of host systemic metabolism on disease 37 
pathobiology remains unclear.  We aimed to examine metabolome profiles and their association 38 
with higher severity, defined by use of positive pressure ventilation (PPV), in infants hospitalized 39 
for bronchiolitis.  40 
Methods: In 140 infants with bronchiolitis, metabolomic profiling was performed on serum: n=70 41 
in the training dataset and n=70 independent samples in the test dataset. We also profiled the 42 
nasopharyngeal airway microbiota and examined its association with the serum metabolites.  43 
Results Serum metabolome profiles differed by bronchiolitis severity (P<0.001). In total, 20 44 
metabolites in the training dataset were significantly associated with the risk of PPV and 18 45 
metabolites remained significant following adjustment for confounders (FDR<0.10). 46 
Phosphatidylcholine metabolites were associated with higher risks of PPV use, while metabolites 47 
from the plasmalogen sub-pathway were associated with lower risks. The test dataset validated 48 
these findings (FDR<0.05). Streptococcus abundance was positively associated with metabolites 49 
that are associated with higher risks of PPV.  50 
Conclusions Serum metabolomic signatures were associated with both the nasopharyngeal 51 
microbiota and bronchiolitis severity. Our findings advance research into the complex interrelations 52 
between airway microbiome, host systemic response, and pathobiology of bronchiolitis. 53 
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INTRODUCTION 57 
  Bronchiolitis is an important public health problem in the US, accounting for 290,000 58 
emergency department visits and 130,000 hospitalizations each year [1–3]. While ~40% of children 59 
develop clinical bronchiolitis in the first two years of life, its severity ranges from a minor nuisance 60 
to fatal [3]. However, these differences in acute severity are not explained by traditionally identified 61 
clinical risk factors (e.g., age, lower body weight, prematurity). Indeed, the pathobiology of 62 
bronchiolitis remains to be elucidated [3]. 63 
 Although bronchiolitis is typically caused by a viral infection, the emerging evidence 64 
suggests a complex interrelationship of respiratory viruses and airway microbiome with local and 65 
systemic host immune response in the pathobiology of bronchiolitis [4–7]. In the airways, a 66 
Streptococcus-dominant microbiome and increased sphingolipid metabolism has been linked to 67 
higher severity of disease [4]. Moving beyond the local site of disease, a recent single-center study 68 
of children with RSV infection reported microbiome-specific systemic immune responses – e.g., 69 
Streptococcus-dominant microbiome was associated with over-expression of genes linked to Toll-70 
like receptor and neutrophil activation in whole blood [8]. However, it remains unclear how these 71 
microbes and the host systemic response influences clinical outcomes by perpetuating downstream 72 
functional molecules. Metabolomics addresses this knowledge gap via comprehensively 73 
characterizing small molecule metabolites that are a function of infant’s genetic makeup and 74 
environmental factors, such as the microbiome [9]. 75 
 In the current study, we aimed to investigate the interrelationships between serum 76 
metabolome, nasopharyngeal airway microbiome, and bronchiolitis severity. We tested the 77 
hypotheses that serum metabolites are associated with the risk of positive pressure ventilation 78 
(PPV) use, and that nasopharyngeal airway bacteria are associated with these identified metabolites 79 
among infants with bronchiolitis.   80 
4 
METHODS 81 
Study design, setting, and participants 82 
 The current study is part of the 35th Multicenter Airway Research Collaboration (MARC-83 
35) [7], a multicenter, prospective cohort study of 1,016 infants (age <1 year) hospitalized for 84 
bronchiolitis. This cohort was coordinated by the Emergency Medicine Network (EMNet), a 85 
collaboration with 245 participating hospitals [10]. The study design, setting, participants, and 86 
methods of data collection have been reported previously [7,11]. Using a standardized protocol, 87 
investigators at 17 sites across 14 U.S. states (Table E1), site investigators enrolled infants 88 
hospitalized with an attending physician diagnosis of bronchiolitis during three consecutive 89 
bronchiolitis seasons from November 1 to April 30 in 2011-2014. Bronchiolitis was defined by the 90 
American Academy of Pediatrics guidelines – i.e., acute respiratory illness with some combination 91 
of rhinitis, cough, tachypnea, wheezing, crackles, and retractions [12]. We excluded infants who 92 
were transferred to a participating hospital >24 hours after the original hospitalization, those who 93 
were consented >24 hours after hospitalization, or those with known heart-lung disease, 94 
immunodeficiency, or gestational age <32 weeks. The institutional review board at each of the 95 
participating hospitals approved the study. We obtained written informed consent from the parent or 96 
guardian. 97 
 In addition to the clinical data (Supplementary Methods), trained site investigators 98 
collected serum and nasopharyngeal airway samples within 24 hours of hospitalization and stored at 99 
−80°C using a standardized protocol [11]. The present analysis investigated a subset of 140 infants 100 
who had, by design, over-representation of rhinovirus infection (Table E2) given its relevance to 101 
respiratory outcomes in childhood [3]. We generated separate training (n=70) and test (n=70) 102 
datasets and profiled their serum metabolome and nasopharyngeal microbiota.  103 
 Ethical approval for this study was obtained from the Human Research Committee at 104 
Massachusetts General Hospital, Protocol 2017P001861. 105 
 106 
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Metabolomic profiling of serum samples 107 
Metabolomic profiling used 100 μl of each serum sample and was performed by Metabolon 108 
(Durham, NC). All samples in each dataset were blinded to Metabolon and processed in a random 109 
order. Metabolome profiling used ultra-high performance liquid chromatography-tandem mass 110 
spectrometry (UPLC-MS/MS). The training and testing datasets were tested separately (March and 111 
September 2017, respectively). Details of the metabolome profiling may be found in the Online 112 
Supplement (Supplementary Methods). Instrument variability was 4% as determined by 113 
calculating the median relative standard deviation for the internal standards that were added to each 114 
sample prior to injection into the mass spectrometers. 115 
 116 
Microbiota and metabolomic testing of nasopharyngeal airway samples 117 
 A complete description of the sequencing and metabolomic protocols for nasopharyngeal 118 
samples is provided in the Online Supplement (Supplementary Methods).  119 
 120 
Statistical analyses 121 
 The primary outcome was the use of PPV – defined as the use of continuous positive airway 122 
pressure and/or intubation – at any time during the index hospitalization [13,14]. Use of PPV is a 123 
clinically relevant and important outcome. 124 
Analysis was first conducted on the training dataset. To examine the differences in the 125 
serum metabolome profiles between infants with PPV use and those without, we performed sparse 126 
partial least squares-discriminatory analysis (sPLS-DA) with 2000 permutations testing [15]. To 127 
determine individual discriminatory metabolites that were significantly associated with the risk of 128 
PPV use, we performed orthogonal partial least squares-discriminatory analysis (OPLS-DA) and 129 
two-tailed Welch’s t-test in MetaboAnalyst 3.0 [16], as well as multivariable linear regression in R 130 
version 3.3 [17]. In the multivariable models, we adjusted for potential confounders (age, sex, 131 
weight at presentation, breastfeeding status, and virus). P-values were adjusted for multiple 132 
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comparisons using the Benjamini-Hochberg false discovery rate (FDR) method [18]. Resulting 133 
FDR values of <0.10 were considered significant for the training dataset and FDR values of <0.05 134 
were considered significant for the test dataset. For the test dataset, only the significant metabolites 135 
derived in the training dataset were analyzed and the same analysis workflow was applied.  136 
To determine the associations between the relative abundance of dominant bacterial genera 137 
in nasopharyngeal airway samples and the intensity of derived serum metabolites, we performed 138 
sparse partial least squares regression (sPLS) analysis in canonical mode using MixOmics [19]. 139 
Lastly, to examine the relations between the airway and circulating metabolome in 70 infants with 140 
the paired samples, we computed the Pearson's correlations between the nasopharyngeal airway and 141 
serum individual metabolites using an existing metabolomic dataset of nasopharyngeal airway 142 
samples from the MARC-35 cohort [4]. Pearson's correlations were plotted with corrplot and FDR 143 
P values were calculated with psych using R. 144 
  145 
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RESULTS 146 
Study population 147 
As part of a 17-center prospective cohort study of 1,016 infants with severe bronchiolitis, 148 
the current investigation analyzed 140 serum samples (70 in the training dataset and 70 in the test 149 
dataset) and nasopharyngeal airway samples obtained at the start of the index hospitalization. The 150 
analytic and nonanalytic cohorts had no significant differences in most patient characteristics 151 
(P>0.05; Table E2), except the analytic cohort had a lower proportion of respiratory syncytial virus 152 
(RSV) and higher proportion of rhinovirus infection. Of the 70 infants in the training dataset, the 153 
median age was 3.7 months (interquartile range, 1.4–5.4 months) and 14 (20%) underwent PPV 154 
during their hospitalization (Table I). While most patient characteristic did not differ between 155 
infants who underwent PPV and those who did not (all P>0.20), the PPV group were significantly 156 
younger and lower in body weight (P<0.05). 157 
 158 
Serum metabolomic profiles were associated with the risk of PPV use among infants with 159 
bronchiolitis 160 
Serum metabolomic testing of infants with bronchiolitis identified a total of 772 metabolites 161 
in the training dataset and 828 metabolites in the test dataset, with 86% overlap between the two 162 
independent datasets. These metabolites were from 91 sub-pathways, contained within 8 super-163 
pathways. sPLS-DA showed that metabolomic profiles of infants with PPV use and those without 164 
PPV use clustered distinctly (P<0.001 with permutation test; Figure 1A).  165 
 In the training dataset, 20 metabolites were significantly associated with the risk of PPV use, 166 
of which 5 were associated with a higher risk of PPV use and 15 with a lower risk of PPV use (FDR 167 
<0.10; Table II). 1-palmitoyl-2-palmitoleoyl-GPC (16:0/16:1) (phosphatidylcholine sub-pathway) 168 
and glucuronate (aminosugar metabolism sub-pathway) were the most significant metabolites 169 
associated with higher risks of PPV use.  170 
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All significant metabolites were from unique sub-pathways, with the exception of 6 metabolites 171 
from the plasmalogen sub-pathway — 1-(1-enyl-palmitoyl)-2-oleoyl-GPE (P-16:0/18:1), 1-(1-enyl-172 
stearoyl)-2-linoleoyl-GPE (P-18:0/18:2), 1-(1-enyl-palmitoyl)-2-linoleoyl-GPE (P-16:0/18:2), 1-(1-173 
enyl-palmitoyl)-2-arachidonoyl-GPE (P-16:0/20:4), 1-(1-enyl-stearoyl)-2-oleoyl-GPE (P-174 
18:0/18:1), and 1-(1-enyl-stearoyl)-2-arachidonoyl-GPE (P-18:0/20:4) — and 2 metabolites form 175 
the fatty acid metabolism sub-pathway — lignoceroylcarnitine (C24) and ximenoylcarnitine 176 
(C26:1) (Figure E1). These plasmalogen metabolites were associated with significantly lower risks 177 
of PPV use. Of the 20 metabolites that are associated with the risk of PPV use, 18 remained 178 
significant following adjustment for confounders and the direction of significant associations was 179 
the same in both analyses (Table II). Likewise, in the OPLS-DA analysis, these significant 180 
metabolites were also among the most discriminatory between the PPV use and non-PPV use 181 
groups (Figure 1B). The heatmap of the 20 significant metabolites also showed clustering of infants 182 
by PPV use (Figure 1C).  183 
To address the possibility of reverse causation (i.e., PPV use alters serum metabolomic 184 
profiles), we repeated the analysis with the use of another severity outcome – hospital length-of-185 
stay (LOS) of ≥3 days [11]. In this sensitivity analysis, metabolomic profiles of infants also differed 186 
significantly by hospital LOS (P<0.001 with permutation test; Figure E2). Likewise, 12 of the 20 187 
significant metabolites were also significantly associated with hospital LOS in the unadjusted 188 
model, with eight metabolites remaining significant following adjustment for confounders 189 
(FDR<0.1; Table E3). In accordance with the analysis for PPV use, 1-palmitoyl-2-palmitoleoyl-190 
GPC (16:0/16:1) was the most significant metabolite associated with longer LOS, while 191 
plasmalogen metabolites were associated with shorter LOS. 192 
 193 
The discriminatory 20 metabolites from the training dataset also separated infants with PPV 194 
use from those with no PPV use in the test dataset 195 
9 
 Using the 20 significant metabolites derived from the training dataset, the metabolomic 196 
profiles remained significantly different (P=0.002 with permutation test) between infants with PPV 197 
use and those with no PPV use in the test dataset (Figure 2A). 1-palmitoyl-2-palmitoleoyl-GPC 198 
(16:0/16:1) was the only metabolite that remained significantly associated with a higher risk of PPV 199 
use (unadjusted FDR<0.001 and adjusted FDR=0.005; Table II). Eleven of 15 metabolites 200 
associated with a lower risk of PPV use remained significant in the test dataset in the unadjusted 201 
model (FDR<0.05; Table II); 6 metabolites remained significant following adjustment (FDR<0.05; 202 
Table II). In the heatmap, consistent with the training dataset analysis, the infants generally 203 
clustered by PPV use. All metabolites associated with higher risks of PPV use clustered distinctly 204 
from the metabolites associated with lower risk of PPV use (Figure 2B).  205 
 206 
Analysis of nasopharyngeal airway microbiota and serum metabolites showed Streptococcus 207 
relative abundance correlates the metabolites associated with risks of PPV use  208 
 Streptococcus, Moraxella, and Haemophilus genera dominated the nasopharyngeal 209 
microbiota, accounting for 80% of the overall relative abundance, in this cohort of infants with 210 
bronchiolitis. Next, we examined how these dominant bacterial bacteria are related to the intensity 211 
of the 20 derived metabolites. The relative abundance of Streptococcus was positively correlated 212 
with the metabolites associated with a higher risk of PPV use (e.g., glucuronate and 1-palmitoyl-2-213 
palmitoleoyl-GPC (16:0/16:1)) and negatively correlated with metabolites associated with a lower 214 
risk of PPV use, including all metabolites from the plasmalogen sub-pathway (i.e., GPEs) in both 215 
the training and test datasets (Figure 3). In contrast, the abundance of Moraxella had the opposite 216 
correlation patterns. 217 
  218 
Nasopharyngeal airway and serum metabolites are not correlated  219 
 In the analysis of 70 infants with paired nasopharyngeal and serum metabolome data, a total 220 
of 225 metabolites from were identified in both datasets (36%). Metabolomic profiles clustered 221 
10 
distinctly between nasopharyngeal and serum samples (P<0.001 with permutation test; Figure 222 
E3A) Of these metabolites detected in both biofluids, 222 of the 225 metabolites had no statistically 223 
significant correlation in intensity between nasopharyngeal airway and serum samples (all 224 
FDR>0.05; Figure E3B).  225 
  226 
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DISCUSSION 227 
 In the current analysis of a multicenter prospective cohort of infants with bronchiolitis, we 228 
employed a metabolomics approach to investigate serum metabolites, and examined their 229 
association with the risk of PPV and hospital LOS. We found that serum metabolomic profiles 230 
differed by disease severity. A total of 20 metabolites were associated with the risk of PPV use in 231 
the training dataset, with 18 metabolites remaining statistically significant after adjustment for 232 
potential confounders. Most significant metabolites were from unique pathways, with the exception 233 
of plasmalogen pathway, from which 6 metabolites (e.g., GPEs) were associated with a lower risk 234 
of PPV use. The test dataset provided validation to the training dataset. Integrating the 235 
nasopharyngeal airway microbiota data from these infants, we also found that the relative 236 
abundance of Streptococcus – one of the pathological bacteria in respiratory health [4,11,20,21] – 237 
was negatively associated with plasmalogen pathway metabolites. To the best of our knowledge, 238 
this is the first study that has investigated the interrelations between airway microbiota, circulating 239 
metabolome, and disease severity in infants with bronchiolitis. 240 
 While bronchiolitis is caused by a viral infection, recent studies have suggested that a 241 
complex interplay between the airway, gut, and host systemic response contributes to the severity of 242 
bronchiolitis (summarized in Figure E4). In the airways, we recently demonstrated in the MARC-243 
35 cohort that infants with a Streptococcus-dominant microbiota had higher severity of illness; this 244 
finding was externally validated in a separate cohort of 307 children hospitalized for bronchiolitis 245 
[11] and was also observed in 234 Australian infants from the Childhood Asthma Study cohort [6]. 246 
Furthermore, studies have also reported interactions between the nasopharyngeal airway microbiota 247 
and airway immune response – which is represented by CCL5 [22] and pro-inflammatory lipid 248 
mediators (e.g., sphingolipid metabolites) [4] in the airway – with regard to acute severity of 249 
bronchiolitis. In the gut, a Bacteroides-dominant fecal microbiota and enhanced sphingolipid 250 
metabolic pathway were associated with a higher likelihood of infant bronchiolitis [23,24]. In 251 
relation to the host systemic response, a recent single-center study of 132 children with RSV 252 
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infection examining nasopharyngeal microbiota and whole blood gene expression reported 253 
microbiota-specific systemic immune responses [8]. Specifically, children with a Streptococcus-254 
dominant nasopharyngeal microbiota had overexpression of genes linked to Toll-like receptor 255 
signaling and chemotactic factors (e.g., interleukin-8) in whole blood [8]. The current multi-omic 256 
analysis corroborates these earlier studies, and extends them by demonstrating the interrelations 257 
between serum metabolome (e.g., glycerophospholipids), airway microbiota (e.g., Streptococcus 258 
abundance), and the risks of PPV use in infants with bronchiolitis.  259 
The mechanisms underlying these interrelations remain to be elucidated. The literature has 260 
suggested that different body sites (and thus sample types) have distinct metabolome profiles 261 
[25,26] and endogenous bacterial communities [27]. Consistently, we also observed no statistically 262 
significant correlations for most individual metabolites between nasopharyngeal airway and serum 263 
samples. It is possible that the unique airway microbiome profile influenced systemic inflammatory 264 
response [8], thereby altering the serum metabolome profile. Alternatively, the microbiome of 265 
distant organs and circulating metabolites might have pertubated the microbiome and local 266 
inflammatory response in the airway. These mechanisms are not mutually exclusive. For example, 267 
the “gut-lung axis” is bidirectional, with changes in either site having subsequent effects on the 268 
other [28]. Previous work has reported that exposing the lungs of mice to bacterial 269 
lipopolysaccharide resulted in changes to the cecum microbiome [29]. Studies have also 270 
demonstrated the effects of gut microbiome on circulating bacterial-derived metabolites (e.g., short-271 
chain fatty acids) – which play a role in the regulation of Th2 and Treg cells – and inflammation in 272 
the airway [30,31]. These observations from the earlier studies and the present study should 273 
advance investigations into the mechanisms underlying the complex interplay between the 274 
microbiome, metabolome, and local and systemic immune responses in infants with bronchiolitis.  275 
Among the 772 serum metabolites identified in the current study, six metabolites (e.g., 276 
GPEs) from the plasmalogen sub-pathway were associated with a lower risk of PPV use. 277 
Plasmalogens are a specific glycerophospholipid class containing a vinyl ether moiety at the sn-1-278 
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position and polyunsaturated fatty acids at sn-2 of the glycerol backbone [32]. Plasmalogens are 279 
primarily considered structural cellular membrane components and reservoirs for second lipid 280 
messengers. Additionally, lung plasmalogens are particularly enriched in arachidonic acid, which 281 
have important roles in inflammation and immunity [32,33]. Plasmalogens also act as endogenous 282 
antioxidants and can protect endothelial cells from hypoxic stress and reactive oxygen species [34]. 283 
The literature has reported that reduced levels of plasmalogens in a range of diseases. In the 284 
airways, reduced plasmalogens have been associated with bronchopulmonary dysplasia in preterm 285 
infants [35], with improved outcomes in infants who received higher amounts of plasmalogen in 286 
surfactant preparations [36]. In a cohort of adults with chronic obstructive pulmonary disease, 287 
smoking was associated with decreased plasmalogen synthesis in the lung, and subsequent 288 
plasmalogen deficiency in the serum [37]. These studies and our data collectively suggest a 289 
potentially protective effect of plasmalogens on respiratory health. 290 
We also found that higher cysteinyl-glycine levels are associated with a higher risk of PPV 291 
use in the training set. This metabolite is related not only to liver diseases (as the product of the 292 
reaction catalyzed by gamma-glutamyl transferase) but also to respiratory diseases (e.g., asthma, 293 
acute respiratory distress syndrome). Cysteinyl-glycine is a substrate of glutathione (gamma-294 
glutamyl-cysteinyl glycine), which is central to redox defense during oxidative stress due to oxidant 295 
and antioxidant imbalance [38,39].  296 
 The current study has several potential limitations. First, the metabolome and microbiota 297 
were measured at a single time-point early in the hospital course of critical illness. While the 298 
consistent findings both in the PPV use and hospital LOS outcomes address, at least in part, 299 
potential reverse causation, longitudinal sampling would facilitate further investigation into 300 
temporal changes preceding disease onset.  Second, we did not have information from a non-301 
bronchiolitis “control” group. Regardless, the study aim was not to evaluate the relationship 302 
between metabolome, microbiota and the development of bronchiolitis, but to investigate their 303 
associations to acute severity among infants with bronchiolitis. Third, the association of serum 304 
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metabolites with bronchiolitis severity represents a novel area of investigation and the applicability 305 
of serum as a biomarker for airway disease requires additional validation and mechanistic 306 
interpretation. However, targeted analysis of serum has revealed lower levels of serum LL-37 307 
associated with higher disease severity [40], providing additional evidence of serum components as 308 
potential biomarkers in bronchiolitis severity. Finally, although our cohort comprised 309 
racially/ethnically-diverse samples, all subjects were hospitalized for bronchiolitis; the inferences 310 
may not be generalizable to infants with mild-to-moderate bronchiolitis. Nevertheless, our findings 311 
are of direct relevance to approximately 130,000 hospitalized children annually in the US [2].  312 
 In conclusion, in this multi-omic analysis of the multicenter data of 140 infants hospitalized 313 
for bronchiolitis, we found that serum metabolome profiles differed by disease severity. In 314 
particular, plasmalogen metabolites, such as GPEs, were associated with a lower risk of PPV use in 315 
both training and test datasets. When we integrated the nasopharyngeal airway microbiota data, we 316 
also found that the relative abundance of Streptococcus was negatively correlated with these 317 
plasmalogen pathway metabolites. While causal relationship remains to be elucidated, prior studies 318 
and the current study collectively suggests that the interrelations between the airway microbiota and 319 
host systemic inflammatory processes – reflected by the circulating metabolome profiles – may 320 
contribute to the bronchiolitis severity (Figure E4). Our data advance understanding of the 321 
mechanism(s) underlying the complex interplay between the airway microbiota and host immune 322 
response, which will facilitate the development of novel preventive and therapeutic strategies in 323 
infants with bronchiolitis. 324 
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TABLES 447 
 448 
Table I. Patient characteristics of infants hospitalized for bronchiolitis by use of positive 449 
pressure ventilation 450 
Data are no. (%) of infants unless otherwise indicated.  451 
Abbreviation: IQR, interquartile range; PPV, positive pressure ventilation; RSV; respiratory syncytial virus 452 
 453 
 Training dataset (n=70) Test dataset  (n=70) 
 
 
Variables 
PPV use 
n=14 
No PPV use  
n=56 
P Value 
PPV use 
n=24 
No PPV use  
n = 46 
P Value 
Characteristics       
Age (mo), median (IQR) 1.5 (1.0-2.8) 3.1 (1.8-5.5) 0.04 1.9 (1.2-5.0) 4.9 (2.5-8.0) 0.051 
Male sex 9 (64%) 40 (71%) 0.85 10 (42%) 28 (61%) 0.20 
Race/ethnicity 
  
0.47   0.49 
     Non-Hispanic white 9 (64%) 23 (41%)  9 (38%) 13 (28%)  
     Non-Hispanic black 2 (14%) 13 (23%)  4 (17%) 10 (22%)  
     Hispanic 3 (21%) 19 (34%)  9 (38%) 22 (48%)  
     Other 0 (0%) 1 (2%)  2 (8%) 1 (2%)  
Maternal smoking during  
   pregnancy 
2 (14%) 9 (16%) 0.99 2 (8%) 4 (9%) 0.99 
Prematurity (32-37 weeks) 3 (21%) 16 (29%) 0.84 6 (25%) 9 (20%) 0.83 
Vaginal delivery 10 (71%) 39 (70%) 0.99 14 (58%) 25 (54%) 0.95 
Mostly breastfed for the first 3  
   months of age 
7 (50%) 29 (52%) 0.75 12 (50%) 18 (39%) 0.53 
Smoke exposure at home 0 (0%) 5 (9%) 0.56 2 (8%) 8 (17%) 0.50 
Clinical presentation       
Weight at presentation (kg),  
   median (IQR) 
5.2 (4.1-6.2) 6.1 (4.6-8.0) 0.049 4.7 (4.0-6.6) 6.9 (5.3-8.2) 0.007 
Respiratory rate at presentation  
   (per minute), median (IQR) 
40 (36-48) 49 (41-60) 0.051 57 (44-72) 49 (40-60) 0.09 
Received corticosteroids during  
   pre-hospitalization visit 
0 (0%) 7 (13%) 0.37 2 (8%) 7 (15%) 0.66 
Virology 
  
0.41   0.07 
Sole RSV infection 10 (71%) 26 (46%)  11 (46%) 16 (35%)  
Sole rhinovirus infection 1 (7%) 10 (18%)  3 (13%) 14 (30%)  
RSV + rhinovirus coinfection 1 (7%) 8 (14%)  1 (4%) 6 (13%)  
Others 2 (14%) 12 (21%)  9 (38%) 10 (22%)  
21 
Table II. Serum metabolites significantly associated with risk of positive pressure ventilation 
use in the training and test datasets 
Metabolite Sub-pathway 
Super-
pathway 
Training dataset Test dataset 
Unadjusted 
model 
FDR* 
Adjusted 
model 
FDR* 
Unadjusted 
model 
FDR* 
Adjusted 
model 
FDR* 
Higher risk of PPV use      
1-palmitoyl-2-palmitoleoyl- 
   GPC (16:0/16:1) 
Phosphatidylch 
   oline (PC) 
Lipid 0.055 0.047 <0.001 0.005 
Bilirubin (E,E) 
 
Hemoglobin  
   and porphyrin  
   metabolism 
Cofactors and  
   vitamins 
0.090 0.180 0.740 0.360 
Cysteinylglycine 
 
Glutathione 
   metabolism 
Amino acid 0.090 0.096 0.200 0.606 
Gucuronate 
 
Aminosugar  
   metabolism 
Carbohydrate 0.029 0.011 0.110 0.890 
Glycerophosphoglycerol 
 
Glycerolipid  
   metabolism 
Lipid 0.072 0.120 0.360 0.760 
       
Lower risk of PPV use      
1-(1-enyl-palmitoyl)-2- 
   arachidonoyl-GPE (P-   
      16:0/20:4) 
Plasmalogen Lipid 0.003 <0.001 0.001 0.055 
1-(1-enyl-palmitoyl)-2-linoleoyl- 
      GPE (P-16:0/18:2) 
Plasmalogen Lipid 0.009 0.005 <0.001 0.014 
1-(1-enyl-palmitoyl)-2-oleoyl- 
   GPE (P-16:0/18:1) 
Plasmalogen Lipid 0.003 <0.001 0.002 0.007 
1-(1-enyl-stearoyl)-2- 
   arachidonoyl-GPE (P-    
   18:0/20:4) 
Plasmalogen Lipid 0.072 0.012 0.013 0.220 
1-(1-enyl-stearoyl)-2-linoleoyl- 
   GPE (P-18:0/18:2) 
Plasmalogen Lipid 0.009 0.002 0.001 0.014 
1-(1-enyl-stearoyl)-2-oleoyl-GPE  
   (P-18:0/18:1) 
Plasmalogen Lipid 0.070 0.015 0.005 0.068 
Carnitine 
Carnitine   
   metabolism 
Lipid 0.012 0.008 0.059 0.501 
Glycochenodeoxycholate sulfate 
 
 
Primary bile  
   acid  
   metabolism 
Lipid 0.009 0.003 0.009 0.150 
Glycosyl-N-(2- 
   hydroxynervonoyl)-sphingosine  
   (d18:1/24:1(2OH)) 
Ceramides Lipid 0.072 0.030 0.095 0.097 
Lignoceroylcarnitine (C24) 
 
Fatty acid  
   metabolism 
Lipid 0.025 0.010 0.023 0.15 
O-acetylhomoserine 
Glycine, serine  
   and threonine  
   metabolism 
Amino acid 0.090 0.003 0.260 0.980 
Retinol (vitamin A) 
 
Vitamin A  
   metabolism 
Cofactors and 
vitamins 
0.009 0.011 0.001 0.010 
Thyroxine 
 
Tyrosine  
   metabolism 
Amino acid 0.090 0.012 0.009 0.037 
Tryptophan 
 
Tryptophan  
   metabolism 
Amino acid 0.072 0.009 <0.001 0.001 
Ximenoylcarnitine (C26:1) 
 
Fatty acid  
   metabolism 
Lipid 0.090 0.075 0.062 0.720 
22 
Abbreviations: GPC, glycerophosphorylcholine; GPE, glycerophosphoethanolamine; FDR, false discovery rate; PPV, 
positive pressure ventilation 
*FDR values of <0.10 considered statistically significant in training dataset and FDR values of <0.05 considered 
significant in the test dataset. Metabolites in bold were significant in all analyses. Age, sex, weight at presentation, 
breastfeeding status, and virus were used in adjusted models. 
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FIGURE LEGENDS  
 
Figure 1. Association of serum metabolome with positive pressure ventilation (PPV) use in the 
training dataset 
(A) Sparse partial least squares–discriminatory analysis (sPLS-DA) score scatter plot per the use of 
PPV (P<0.001 with 2000 random permutations). Each dot is the representation of the serum 
metabolomic profile of a single patient in a two-dimensional space. The ellipses represent the 95% 
confidence interval.  
(B) Orthogonal partial least squares–discriminatory analysis (OPLS-DA) loadings plot. The 20 
metabolites that are significantly different between the PPV use and non-PPV use groups are 
shown. Metabolites are colored according to being associated with a higher risk (red) or lower risk 
(blue) of PPV use.  
(C) Heatmap of the 20 metabolites significantly different between the PPV use and non-PPV use 
groups. Clustering based on Euclidean distance and Ward linkage. The patients are shown in 
columns – the PPV use group (red) and the non-PPV use group (blue). The intensity of metabolites 
is shown with the color representing the log-transformed metabolite intensity, where blue is low and 
red is high. The row dendrogram is colored according to the metabolite being increased in PPV use 
(red) or no PPV use (blue). 
 
 
Figure 2. Association of serum metabolome with positive pressure ventilation (PPV) use in the 
test dataset  
Data based on serum metabolites among infants with PPV use (n=24) compared to those with no 
PPV use (n = 46).  
(A) Sparse partial least squares–discriminatory analysis (sPLS-DA) score scatter plot of the test 
dataset, grouped according to the use of PPV (P=0.002 with 2000 random permutations). Each dot 
24 
is the representation of the serum metabolomic profile of a single patient in a two-dimensional 
space. The ellipses represent the 95% confidence interval.  
(B) Heatmap analysis of the test dataset based on the 20 metabolites significantly different between 
PPV use and no PPV use that are derived in the training dataset. Clustering based on Euclidean 
distance and Ward linkage. The patients are shown in columns – the PPV use group (red) and the 
non-PPV use group (blue). Metabolites are shown in rows with the color representing the log 
transformed metabolite intensity, where blue is low and red is high. The row dendrogram is colored 
according to the metabolite being increased in PPV use (red) or no PPV use (blue). 
 
 
Figure 3. Canonical correlation between nasopharyngeal microbiota associated with positive 
pressure ventilation (PPV) use 
A) Training dataset. B) Test dataset. The top three dominant bacterial genera (Haemophilus, 
Moraxella, and Streptococcus), which together represent 80% of the overall abundance, are shown. 
Relative abundance for the three dominant genera is based on 16S rRNA gene sequencing. The 20 
discriminatory metabolites are shown in rows with the dendrogram colored according to the 
metabolite associated with higher risks of PPV use (red) or lower risks of PPV use (blue).  
 
 
 
 
